Akero Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Akero Therapeutics (Nasdaq: AKRO) announced its participation at the 40^th Annual J.P. Morgan Healthcare Conference on January 11, 2022, at 10:30 a.m. E.T. The live presentation will be accessible via the investor relations section of their website, with archived replays available afterward.

Akero is focused on developing therapies for serious metabolic diseases, particularly non-alcoholic steatohepatitis (NASH). Their lead candidate, efruxifermin (EFX), is undergoing Phase 2b trials and aims to provide a groundbreaking treatment option for patients.

SOUTH SAN FRANCISCO, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will present at the 40^th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11 at 10:30 a.m. E.T.

A live webcast of the Company presentation will be available through the investor relations section of the Company's website at www.akerotx.com. Following the live webcasts, archived replays will be available on the Company's website.

About Akero Therapeutics
Akero Therapeutics is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Akero's lead product candidate, efruxifermin (EFX), is a differentiated Fc-FGF21 fusion protein that has been engineered to mimic the balanced biological activity profile of native FGF21, an endogenous hormone that alleviates cellular stress and regulates metabolism throughout the body. EFX is designed to offer convenient once-weekly subcutaneous dosing. The consistency and magnitude of observed effects position EFX to be a potentially best-in-class medicine, if approved, for treatment of NASH. EFX is currently being evaluated in two Phase 2b clinical trials: the HARMONY study in pre-cirrhotic patients with F2/F3 fibrosis and the SYMMETRY study in compensated cirrhotic (F4) patients. Akero is headquartered in South San Francisco. Visit us at www.akerotx.com for more information.

Investor Contact:
Christina Tartaglia
Stern Investor Relations, Inc.
212.362.1200
christina.tartaglia@sternir.com

Media Contact:
650.487.6488
media@akerotx.com

FAQ

What is Akero Therapeutics presenting at the J.P. Morgan Healthcare Conference?

Akero Therapeutics will present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022, at 10:30 a.m. E.T.

How can I watch Akero Therapeutics' presentation?

The presentation can be viewed live through the investor relations section of Akero Therapeutics' website.

What is efruxifermin (EFX) and its significance?

Efruxifermin (EFX) is Akero's lead product candidate designed for treating non-alcoholic steatohepatitis (NASH), currently in Phase 2b clinical trials.

What conditions does Akero Therapeutics focus on?

Akero Therapeutics develops treatments primarily for serious metabolic diseases, notably non-alcoholic steatohepatitis (NASH), which has no approved therapies.

What are the ongoing clinical trials for Akero Therapeutics?

Akero is conducting two Phase 2b clinical trials: the HARMONY study for pre-cirrhotic patients and the SYMMETRY study for compensated cirrhotic patients.